Crow Point Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

Crow Point Partners’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$323K	Buy	64,210 +210	+0.3%	+$1.2K	0.05%	149
2015 Q2	$412K	Buy	+64,000	New	+$429K	0.06%	137
2014 Q3	–	Sell	-13,330	Closed	-$111K	–	301
2014 Q2	$111K	Hold	13,330	–	–	0.01%	173
2014 Q1	$111K	Buy	+13,330	New	+$114K	0.01%	173

Other funds holding PDLI

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Crow Point Partners's PDLI Position: Q3 2015 in Review

Crow Point Partners increased its PDL BioPharma, Inc. (PDLI) stake by 0.33% in Q3 2015, buying an estimated $1.2K and bringing the position to 64,210 shares worth $323K. The position accounts for 0.05% of the portfolio, ranked #149.

Crow Point Partners first reported a position in PDLI in Q1 2014 and has held it in 4 quarters since. The position peaked at $412K in Q2 2015. 213 funds tracked by Wall St. Rank hold PDLI as of Q3 2015.

Crow Point Partners held 64,210 shares of PDL BioPharma, Inc. worth $323K as of Q3 2015.
Crow Point Partners bought 210 PDL BioPharma, Inc. shares in Q3 2015, an estimated $1.2K.
PDL BioPharma, Inc. made up 0.05% of Crow Point Partners's portfolio in Q3 2015, its #149 holding.
Crow Point Partners first reported a position in PDL BioPharma, Inc. in Q1 2014 and has held it in 4 quarters since.
Crow Point Partners's PDL BioPharma, Inc. position peaked at $412K in Q2 2015.
213 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2015.

Based on Crow Point Partners's 13F filing for Q3 2015, filed 17 Dec 2015.